

APPLIED DNA SCIENCES INC  
Form 8-K  
April 04, 2007

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): March 30, 2007**

**Applied DNA Sciences, Inc**

(Exact Name of Registrant as Specified in Charter)

**Nevada**  
(State or Other Jurisdiction  
of Incorporation)

**002-90539**  
(Commission File Number)

**59-2262718**  
(IRS Employer  
Identification No.)

**25 Health Sciences Drive, Suite 113  
Stony Brook, New York 11790**  
(Address of Principal Executive Offices) (Zip Code)

**631-444-6861**  
(Registrant's telephone number, including area code)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: APPLIED DNA SCIENCES INC - Form 8-K

- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On April 4, 2007, Applied DNA Sciences, Inc. (the “Company”) issued a press release to announce that the parties to the Sub-License Agreement dated July 29, 2003, by and between the Company, Biowell Technology, Inc. and G.A. Corporate Finance Ltd., have terminated such Sub-License Agreement, and that in connection with such termination all of G.A. Corporate Finance Ltd.’s interests in Applied DNA Sciences Europe Ltd. have been transferred to the Company. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

Exhibit 99.1 Press release of Applied DNA Sciences, Inc., dated April 4, 2007.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Applied DNA Sciences, Inc.**  
(Registrant)

By: /s/ James Hayward  
James Hayward  
Chief Executive Officer

Date: April 4, 2007

---

Edgar Filing: APPLIED DNA SCIENCES INC - Form 8-K

Exhibit No.

Description of Exhibit

99.1

Press Release of Applied DNA Sciences, Inc., dated April 4, 2007.